Cargando…

Digital therapeutics and clinical pharmacology

Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists. In this article, an overview of DTx, including definition, position in the landscape of therapeutics, product categories, benefits, and cha...

Descripción completa

Detalles Bibliográficos
Autor principal: Chung, Jae-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989269/
https://www.ncbi.nlm.nih.gov/pubmed/32055575
http://dx.doi.org/10.12793/tcp.2019.27.1.6
_version_ 1783492371830276096
author Chung, Jae-Yong
author_facet Chung, Jae-Yong
author_sort Chung, Jae-Yong
collection PubMed
description Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists. In this article, an overview of DTx, including definition, position in the landscape of therapeutics, product categories, benefits, and challenges, is provided. Discussions from the point of view of clinical pharmacology are presented, as DTx should have exposure-response relationships. The principles of clinical pharmacology can be applied to DTx as they are comparable to pharmacotherapy. Clinical pharmacology has great potential in the development, application, and regulation of DTx.
format Online
Article
Text
id pubmed-6989269
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Society for Clinical Pharmacology and Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-69892692020-02-13 Digital therapeutics and clinical pharmacology Chung, Jae-Yong Transl Clin Pharmacol Review Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists. In this article, an overview of DTx, including definition, position in the landscape of therapeutics, product categories, benefits, and challenges, is provided. Discussions from the point of view of clinical pharmacology are presented, as DTx should have exposure-response relationships. The principles of clinical pharmacology can be applied to DTx as they are comparable to pharmacotherapy. Clinical pharmacology has great potential in the development, application, and regulation of DTx. Korean Society for Clinical Pharmacology and Therapeutics 2019-03 2019-03-27 /pmc/articles/PMC6989269/ /pubmed/32055575 http://dx.doi.org/10.12793/tcp.2019.27.1.6 Text en Copyright © 2019 Jae-Yong Chung http://creativecommons.org/licenses/by-nc/3.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).
spellingShingle Review
Chung, Jae-Yong
Digital therapeutics and clinical pharmacology
title Digital therapeutics and clinical pharmacology
title_full Digital therapeutics and clinical pharmacology
title_fullStr Digital therapeutics and clinical pharmacology
title_full_unstemmed Digital therapeutics and clinical pharmacology
title_short Digital therapeutics and clinical pharmacology
title_sort digital therapeutics and clinical pharmacology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989269/
https://www.ncbi.nlm.nih.gov/pubmed/32055575
http://dx.doi.org/10.12793/tcp.2019.27.1.6
work_keys_str_mv AT chungjaeyong digitaltherapeuticsandclinicalpharmacology